EIKON THERAPEUTICS INC (EIKN) competitors & alternatives
Health Care · NASDAQ
EIKON THERAPEUTICS INC (EIKN)'s top competitors and alternatives — its most similar public companies — include RAPPORT THERAPEUTICS INC (RAPP), MONTE ROSA THERAPEUTICS INC (GLUE), Revolution Medicines (RVMD), AURA BIOSCIENCES INC (AURA), UNICYCIVE THERAPEUTICS INC (UNCY), CONNECT BIOPHARMA HOLDINGS LTD (CNTB), LEXICON PHARMACEUTICALS INC (LXRX), SELLAS LIFE SCIENCES GROUP INC (SLS), CULLINAN THERAPEUTICS INC (CGEM), MAZE THERAPEUTICS INC (MAZE), GENERATE BIOMEDICINES INC (GENB) and MBX BIOSCIENCES INC (MBX). These are EIKON THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top EIKN competitors & alternatives
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
MONTE ROSA THERAPEUTICS INCGLUEHealth Care
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its…
$23.79 (as of 2026-07-22) · market cap $2.0B
-
Revolution MedicinesRVMDHealth Care
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
$183.03 (as of 2026-07-22) · market cap $39.0B
-
AURA BIOSCIENCES INCAURAHealth Care
Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving…
$7.01 (as of 2026-07-22) · market cap $725M
-
UNICYCIVE THERAPEUTICS INCUNCYHealth Care
A clinical-stage biotechnology firm developing nanoparticle-based and novel therapies to address significant unmet medical needs in kidney disease.
$5.57 (as of 2026-07-22) · market cap $149M
-
CONNECT BIOPHARMA HOLDINGS LTDCNTBHealth Care
Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD.
$2.20 (as of 2026-07-22) · market cap $139M
-
LEXICON PHARMACEUTICALS INCLXRXHealth Care
An early-stage commercial biopharmaceutical company with a gene-discovery platform advancing cardiovascular and metabolic therapies, headlined by…
$2.25 (as of 2026-07-22) · market cap $1.0B
-
SELLAS LIFE SCIENCES GROUP INCSLSHealth Care
SELLAS Life Sciences is a clinical-stage biotech developing targeted immunotherapies and small molecule inhibitors to treat a variety of hematologic and solid…
$12.08 (as of 2026-07-22) · market cap $2.2B
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
MAZE THERAPEUTICS INCMAZEHealth Care
Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease…
$28.49 (as of 2026-07-22) · market cap $1.6B
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
MBX BIOSCIENCES INCMBXHealth Care
A clinical-stage biopharmaceutical company leveraging a proprietary platform to optimize drug candidate properties and develop therapies across multiple…
$58.30 (as of 2026-07-22) · market cap $2.9B
Not quite? Describe exactly what you want →
Peers are EIKON THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: EIKON THERAPEUTICS INC (EIKN).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.